1. Home
  2. INLX vs INZY Comparison

INLX vs INZY Comparison

Compare INLX & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INLX
  • INZY
  • Stock Information
  • Founded
  • INLX 1996
  • INZY 2015
  • Country
  • INLX United States
  • INZY United States
  • Employees
  • INLX N/A
  • INZY N/A
  • Industry
  • INLX EDP Services
  • INZY Biotechnology: Pharmaceutical Preparations
  • Sector
  • INLX Technology
  • INZY Health Care
  • Exchange
  • INLX Nasdaq
  • INZY Nasdaq
  • Market Cap
  • INLX 60.5M
  • INZY 64.9M
  • IPO Year
  • INLX N/A
  • INZY 2020
  • Fundamental
  • Price
  • INLX $14.47
  • INZY $1.24
  • Analyst Decision
  • INLX
  • INZY Strong Buy
  • Analyst Count
  • INLX 0
  • INZY 9
  • Target Price
  • INLX N/A
  • INZY $17.22
  • AVG Volume (30 Days)
  • INLX 3.5K
  • INZY 1.1M
  • Earning Date
  • INLX 05-16-2025
  • INZY 05-20-2025
  • Dividend Yield
  • INLX N/A
  • INZY N/A
  • EPS Growth
  • INLX N/A
  • INZY N/A
  • EPS
  • INLX N/A
  • INZY N/A
  • Revenue
  • INLX $18,018,373.00
  • INZY N/A
  • Revenue This Year
  • INLX $7.58
  • INZY N/A
  • Revenue Next Year
  • INLX N/A
  • INZY N/A
  • P/E Ratio
  • INLX N/A
  • INZY N/A
  • Revenue Growth
  • INLX 6.70
  • INZY N/A
  • 52 Week Low
  • INLX $5.85
  • INZY $0.72
  • 52 Week High
  • INLX $16.50
  • INZY $6.24
  • Technical
  • Relative Strength Index (RSI)
  • INLX 55.56
  • INZY 54.98
  • Support Level
  • INLX $12.00
  • INZY $1.18
  • Resistance Level
  • INLX $14.99
  • INZY $1.63
  • Average True Range (ATR)
  • INLX 0.67
  • INZY 0.19
  • MACD
  • INLX -0.09
  • INZY 0.03
  • Stochastic Oscillator
  • INLX 66.40
  • INZY 36.13

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About INZY Inozyme Pharma Inc.

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

Share on Social Networks: